On the basis of these results, we performed a randomized phase 2 clinical trial to determine the value of combined selective COX-2 inhibition with standard concurrent chemoradiation therapy (CCRT) among patients with unresectable stage III NSCLC, with a focus on survival, treatment-related lung toxic effects, and the association of the COX-2 and −1195G>A polymorphism with overall survival (OS). The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.